Daniel Elias Martin Herranz EMBL-EBI

PhD goals: why not start a company?

EMBL-EBI PhD student launches start-up focusing on epigenetics and wellbeing

By Oana Stroe

Lab Matters

Celgene logo on white background

Celgene joins Open Targets

New partner strengthens drug discovery collaboration

By Oana Stroe

Lab Matters

EMBL spinoff Velabs Therapeutics to help antibody discovery. IMAGE: Velabs Therapeutics

EMBL spinoff to help antibody discovery

New EMBL spinoff company Velabs Therapeutics aims to speed up discovery of therapeutic antibodies

By Iris Kruijen

Lab Matters

10x Genomics joined EMBL's Corporate Partnership Programme

10x Genomics joins EMBL’s Corporate Partnership Programme

Joining forces for single-cell research

By Sonia Furtado Neves

Lab Matters

Takeda logo on white background

Takeda joins drug target discovery initiative

Takeda joins pioneering public-private drug discover collaboration Open Targets

By Oana Stroe

Lab Matters

A photo of the Earth

EMBL and HeidelbergCement explore ways to reduce carbon

EMBL and HeidelbergCement sign Memorandum of Understanding

By Berta Carreño

Lab Matters

Revathi Nathaniel, UX expert at EMBL-EBI.

UX toolkit aids industry R&D

Exploring the potential of user experience for life sciences through industry workshops

By Oana Stroe


EMBL spin-off Luxendo acquired by Bruker

Accelerating researchers’ access to next-generation light-sheet microscopy

By Sonia Furtado Neves

Lab Matters

Pathways: Life science investment

EMBL alumnus Joep Muijrers talks about making the transition from science into business

By Edward Dadswell


Turning up the heat on drug side effects

Side-effects of leukaemia drug explained, reveal possibility of repurposing to treat other diseases

By Adam Gristwood



Read the latest Issues of our magazine - EMBLetc.

Looking for past print editions of EMBLetc.? Browse our archive, going back 20 years.

EMBLetc. archive